Nautilus Biotechnology (NASDAQ:NAUT) Coverage Initiated at Guggenheim

Guggenheim started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT) in a research report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $6.00 target price on the stock.

Separately, Jefferies Financial Group began coverage on shares of Nautilus Biotechnology in a research report on Monday, June 3rd. They set a hold rating and a $3.00 target price for the company.

Nautilus Biotechnology Price Performance

Shares of NAUT opened at $2.34 on Thursday. The firm has a market capitalization of $293.11 million, a PE ratio of -4.25 and a beta of 1.25. Nautilus Biotechnology has a 1-year low of $2.19 and a 1-year high of $4.00. The company’s fifty day moving average price is $2.61 and its 200-day moving average price is $2.76.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. As a group, research analysts anticipate that Nautilus Biotechnology will post -0.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its position in Nautilus Biotechnology by 38.2% during the fourth quarter. Perceptive Advisors LLC now owns 12,594,211 shares of the company’s stock valued at $37,657,000 after purchasing an additional 3,483,060 shares during the period. Vanguard Group Inc. raised its position in shares of Nautilus Biotechnology by 1.0% in the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock worth $8,407,000 after acquiring an additional 29,604 shares during the period. SG Americas Securities LLC raised its position in shares of Nautilus Biotechnology by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 28,606 shares of the company’s stock worth $86,000 after acquiring an additional 6,234 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Nautilus Biotechnology by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock worth $71,000 after acquiring an additional 9,624 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after acquiring an additional 4,239 shares during the period. 50.71% of the stock is currently owned by institutional investors and hedge funds.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.